Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD

Blood (2018) 132 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2018-99-114723

Published: 2018

Journal Articles

Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo , and Is Being Evaluated Clinically in Patients with B-Cell Malignancies

Ida H. Hiemstra, PhD, Patrick J. Engelberts, BS, Bart de Jong, BS, Danita H Schuurhuis, PhD, Theodora W. Salcedo, PhD DABT, Sandra Verploegen, PhD, Marten van der Zee, PhD, Arnout F. Gerritsen, PhD, Nedjad Losic, PhD, Sjeng Horbach, PhD, Roberto Oliveri, MD PhD, Jeroen J. Lammerts van Bueren, PhD, Pernille Autzen Usher, PhD, Janine Schuurman, PhD, Paul W. H. I. Parren, PhD, Esther C. W. Breij, PhD

Blood (2018) 132 (Supplement 1): 1664.

https://doi.org/10.1182/blood-2018-99-115957

Published: 2018

Journal Articles

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Inger S. Nijhof, MD, Jeroen Lammerts van Bueren, Berris van Kessel, Michel de Weers, Joost M Bakker, PhD, Paul W. H. I. Parren, PhD, Henk Lokhorst, MD, PhD, Tuna Mutis, MD PhD

Blood (2012) 120 (21): 4988.

https://doi.org/10.1182/blood.V120.21.4988.4988

Published: 2012

Journal Articles

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Yu-Tzu Tai, Ph.D., Michel de Weers, Ph.D., Xian-Feng Li, MS, Weihua Song, MD, Sabikun Nahar, B.S., Joost M Bakker, Tom Vink, Daniëlle Jacobs, Lukas Oomen, Wim K Bleeker, Nikhil C. Munshi, MD, Jan G. J. van de Winkel, PhD, Paul W. H. I. Parren, PhD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 608.

https://doi.org/10.1182/blood.V114.22.608.608

Published: 2009

Journal Articles

Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC.

Jenny L Craigen, PhD, Wendy J.M. Mackus, PhD, Patrick Engleberts, Sam R Miller, Sue Speller, Louise C Chamberlain, Bill G Davis, PhD, Simon M McHugh, PhD, Ed Bullmore, PhD, Charles J Cox, PhD, Sally Wetten, Gerrard Perdock, Joost M Bakker, PhD, Jan G. J. van de Winkel, PhD, Paul W. H. I. Parren, PhD

Blood (2009) 114 (22): 1725.

https://doi.org/10.1182/blood.V114.22.1725.1725

Published: 2009

Journal Articles

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Ronald P. Taylor, PhD, Paul V. Beum, PhD, P. Todd Stukenberg, PhD, Andrew W. Pawluczkowycz, MS, Margaret A. Lindorfer, PhD, Frank J. Beurskens, PhD, Paul W. H. I. Parren, PhD, Jan G. J. van de Winkel, PhD

Blood (2008) 112 (11): 1577.

https://doi.org/10.1182/blood.V112.11.1577.1577

Published: 2008

Journal Articles

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Ronald P. Taylor, PhD, Andrew W. Pawluczkowycz, MS, Margaret A. Lindorfer, PhD, Jan G. J. van de Winkel, PhD, Frank J. Beurskens, PhD, Paul W. H. I. Parren, PhD

Blood (2008) 112 (11): 1578.

https://doi.org/10.1182/blood.V112.11.1578.1578

Published: 2008

NARROW

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo , and Is Being Evaluated Clinically in Patients with B-Cell Malignancies

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC.

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Email alerts

ASH Publications

American Society of Hematology

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo , and Is Being Evaluated Clinically in Patients with B-Cell Malignancies

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC.

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only